Tiger's Take: $SGMOOn our trading list, a small biotech with great potential. Keep in mind though it is also in the "high risk/high reward" category. Good news in preclinical data recently. Still very early, but potential is really high.NOTE: Up 30% on Tuesday. Some of my readers said they "missed" it. Well there is a pullback now based on this offering. 2nd chance... Down a bit after hours on the news at 11.95ish.Sangamo Spot Secondary; re-offered at $11.50The deal size is $115M in common stock re-offered at $11.50. Cowen, Wells Fargo and Barclays are acting as joint book running managers for the offering.Read more at: (source)https://thefly.com/landingPage... $SGMO, Sangamo Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.